We are live on ! Find out more

Absci

ABSI

Market cap $1.49B

8.71 USD

-0.71

7.54%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

8.75

+0.04

0.46%

1 day

-7.54%

5 days

-6.65%

1 month

22.16%

3 months

43.26%

6 months

211.07%

Year to date

141.27%

1 year

252.63%

5 years

-52.17%

10 years

-59.66%

About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.

Employees: 140

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 44.4%

Neutral 44.4%

Negative 11.1%

24/7 Wall Street

AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next

On August 14, 2026, Advanced Micro Devices (NASDAQ:AMD | AMD Price Prediction) filed its first-ever 13F, pulling back the curtain on a $1.31 billion equity portfolio concentrated in just six positions.

AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next

Zacks Investment Research

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript

Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript

Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript

Absci Q2 Earnings Call Highlights

Absci NASDAQ: ABSI outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from Eli Lilly.

Absci Q2 Earnings Call Highlights

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026.

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Zacks Investment Research

Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?

Here is how Absci Corporation (ABSI) and Acadia Healthcare (ACHC) have performed compared to their sector so far this year.

Are Medical Stocks Lagging ABSCI CORP (ABSI) This Year?

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026.

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

Zacks Investment Research

Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know

Zacks Investment Research

Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy

Does Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy

Healthcare stocks have become a haven for investors ditching tech

Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.

Healthcare stocks have become a haven for investors ditching tech

See News Rankings

Price charts implemented using Lightweight Charts™